TFFP earnings

Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue to Demonstrate Antifungal Activity and a Favorable Safety and Tolerability Profile TFF TAC Program Prioritized Based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and Substantial Market Opportunity Company to Hold Conference Call and Webcast Today at 4:30 pm ET FORT WORTH, Texas , March 27, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing

Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and Substantial Market Opportunity Company to Evaluate Strategic Options for TFF VORI, including Partnerships, Collaborations, and Grants following Positive Data from Phase 2 Study and the Expanded Access Program (EAP) Company to Discuss Clinical Updates on TFF TAC and TFF VORI on Wednesday, March 27, 2024 at 4:30 pm ET FORT WORTH, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing an

Treatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause mortality, no invasive pulmonary aspergillosis (IPA)-related mortality, and no TFF VORI discontinuations due to an adverse event (AE) Successful transition of all four patients from oral tacrolimus to TFF TAC, leading to significant lowering of tacrolimus blood levels with no clinical evidence of acute rejection; all patients who completed Part A (study treatment period) of the trial chose to remain on TFF TAC and advance to Part B (extension study) TFF TAC was well tolerated, with no mortality a

FORT WORTH, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company will hold a conference call and webcast to review initial data from the ongoing Phase 2 trials of TFF VORI and TFF TAC on Tuesday, December 19th at 8:30 am ET. Conference Call and Webcast InformationTo participate in the conference call, please utilize the following information: Domestic Dial-In Number: Toll-Free: 1-877-407-3982 International Dial-In Number: 1-201-493-6780

FORT WORTH, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it management will host a conference call to discuss the financial results for the second quarter of 2023 and provide an update on recent corporate and clinical developments on Tuesday, August 15, 2023, at 11:00 AM ET. A question-and-answer session with investors will follow management's remarks. Conference Call and Webcast Information The Company will host a conference call on Tuesday, August 15, 20

Initial Phase 2 data for TFF VORI and TFF TAC expected later this yearExpanded compassionate use program for TFF VORIEntered into CRADA with National Institute of Environmental Health Sciences Extended contract with Leidos providing additional funding for TFF's development of next-generation countermeasuresImplemented reduced spending initiatives to extend cash runway through year-end FORT WORTH, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financi

Dr. Harlan Weisman and recently appointed Chief Medical Officer Dr. Zamaneh Mikhak to Provide an Overview of the Corporate Strategy and 2023 Objectives Conference Call and Webcast Scheduled for Thursday, February 16, 2023, 4:30 p.m. ET FORT WORTH, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced the appointment of Harlan Weisman, M.D. as permanent Chief Executive Officer. TFF Pharmaceuticals will hold a conference call and webcast on February 16 to provide an ove

Clinical Proof-of-Concept Demonstrated in Compassionate Use in Two Case Studies with Voriconazole Inhalation Powder (TFF VORI)   Growing Body of Peer-Reviewed Scientific Literature Provides Foundations for Expanding Applications of Thin Film Freezing Feasibility Study Agreement with Aptar Pharma to Explore Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics Conference Call and Webcast Scheduled Today, Monday, November 14, 2022, at 4:30 PM ET FORT WORTH, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thi

Company conference call and webcast at 4:30 PM ET FORT WORTH, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that it will release its financial results and business update for the third quarter of 2022 on Monday, November 14, 2022, at the close of the U.S. financial markets. Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at 4:30 PM ET. A question-and-answer session with investo

Phase 2 Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder Programs Continue to Advance Expands R&D Operations with New Austin, TX Facility Recent Feasibility Work Confirms Utility of Thin Film Freezing in Developing Next- Generation Vaccines Conference Call and Webcast Scheduled Today, Thursday, August 11, 2022, at 4:30 PM ET FORT WORTH, Texas, Aug. 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the second quarter of 202

FORT WORTH, Texas, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results and business update for the second quarter of 2022 on Thursday, August 11, 2022, at the close of the U.S. financial markets. Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at 4:30 PM ET. A question-and-answer session with investors will follow management's remarks. Co

Announced Collaboration with Catalent to Further Expand Thin Film Freezing Applications with a Focus on Biologic Drug Development Announced Second CRADA Agreement with USAMRIID and Geneva Foundation to Develop Novel Therapies Using Thin Film Freezing to Combat SARS-CoV-2, Ebola, and Marburg Viruses Initiated Phase 2 Trials of Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder With Interim Data for Each Program Expected Later in 2022 Significant Progress Made in Inhaled Niclosamide Powder Program Multiple Abstracts Highlighting Applications of Thin Film Freezing Presented at Respiratory Drug Delivery (RDD) Meeting Conference Call and Webcast Scheduled Today, Wednesday, May 11, 202

FORT WORTH, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results and business update for the first quarter of 2022 on Wednesday, May 11, 2022, after the close of the U.S. financial markets. Conference Call and Webcast Information The Company will host a conference call on Wednesday, May 11, 2022, at 4:30 PM ET to review the clinical, corporate and financial highlights. A question-and-answer session with investors will follow

Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs Partnership Activity Surrounding Thin Film Freezing Continues to Expand Reflecting the Technology's Broad Applicability Across Molecule Type and Therapeutic Area Appoints Life Sciences Executive, Brandi Roberts, to Board of Directors and Anthony Hickey, Ph.D. as Chief Scientific Officer Expands Leadership Team With Senior Appointments in Product Development and Manufacturing, Government and Strategic Initiatives, and Regulatory Affairs Conference Call and Webcast Scheduled Today, Thursday, March 24, 2022, at 4:30 PM ET FORT WORTH, Texas, March 24, 2022 (GLOBE NEWSWIRE) -- TFF Pharma

AUSTIN, Texas, March 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results and business update for the fourth quarter of 2021 on Thursday, March 24, 2022, at the close of the U.S. financial markets. Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at 4:30 PM ET. A question-and-answer session with investors will follow management's remarks. Conference

Positive Updates Announced for Inhaled Voriconazole and Tacrolimus Programs;Both Programs Advancing into Phase 2 Testing Continued Progress with Partnered Antiviral Programs for AUG-3387 and Niclosamide Thin Film Freezing Applications Continue to Expand Across Diverse Set of Drug Candidates; IP Estate Now Includes Over 120 Patents Granted or Pending Conference Call and Webcast Scheduled Today, Monday, November 15, 2021, at 4:30 PM ET AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technol

AUSTIN, Texas, Nov. 05, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results and business update for the third quarter of 2021 on Monday, November 15, 2021, at the close of the U.S. financial markets. Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at 4:30 PM ET. A question-and-answer session with investors will follow management's remarks. Confere

Additional Data Readouts and Initiation of Pivotal Trials for Inhaled Tacrolimus and Voriconazole Programs Expected in 2H 2021 Multiple Ascending Dose (MAD) Study Demonstrates Inhaled Tacrolimus Inhalation Powder Achieves Blood Levels Sufficient for Efficacious Immunosuppression Formation of Scientific Advisory Board to Enable Continued Innovation and Clinical Development Partnerships with Pharma, Academic Institutions and Government Continue to Advance Conference Call and Webcast Scheduled Today, Thursday, August 12, 2021, at 4:30pm EDT AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceutica

AUSTIN, Texas, Aug. 04, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results and business update for the second quarter of 2021 on Thursday, August 12, 2021, at the close of the U.S. financial markets. Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at 4:30 PM EDT. A question-and-answer session with investors will follow management's remarks. Conferenc